Abiopharma

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Symbol	AAPG
Name	ASCENTAGE PHARMA GROUP INTERNATIONAL
Sector	HEALTH CARE
Region	Asia
Industry	Biotechnology: Pharmaceutical Preparations
Address	68 XINQING ROAD,SUZHOU INDUSTRIAL PARK, SUZHOU, China
Telephone	86 512 8555 7777
Fax	—
Email	—
Website	https://www.ascentagepharma.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	—
Description	Ascentage Pharma Group is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. We have eleven completed or ongoing U.S. and/or international registrational trials, including two that are FDA-regulated, for our five key clinical-stage assets. Additional info from NASDAQ: Ascentage Pharma Group is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Our lead assets, olverembatinib and lisaftoclax, have global potential to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. We are the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. We have eleven completed or ongoing U.S. and/or international registrational trials, including two that are FDA-regulated, for our five key clinical-stage assets.

2026-04-21 17:37

Misra Veet 🟢 acquired 18.6K shares (1 derivative) of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Transaction Date: Apr 20, 2026 | Filing ID: 046036

2026-04-21 14:37

New Form 3 - ASCENTAGE PHARMA GROUP INTERNATIONAL Filed: 2026-04-21 AccNo: 0001213900-26-046034 Size: 9 KB

2026-04-20 12:56

New Form 3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL Filed: 2026-04-20 AccNo: 0001213900-26-045441 Size: 11 KB

2026-04-20 12:30

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Files Form 6-K

2026-04-10 12:51

New Form 3 - ASCENTAGE PHARMA GROUP INTERNATIONAL Filed: 2026-04-10 AccNo: 0001213900-26-042283 Size: 10 KB

2026-04-01 20:30

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Files Form 6-K

2026-03-26 12:00

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Files Form 6-K

2026-03-23 21:01

New Form 3 - ASCENTAGE PHARMA GROUP INTERNATIONAL Filed: 2026-03-23 AccNo: 0001213900-26-033149 Size: 18 KB

2026-03-23 20:24

New Form 3 - ASCENTAGE PHARMA GROUP INTERNATIONAL Filed: 2026-03-23 AccNo: 0001213900-26-033135 Size: 12 KB

2026-03-23 20:22

New Form 3/A - ASCENTAGE PHARMA GROUP INTERNATIONAL Filed: 2026-03-23 AccNo: 0001213900-26-033134 Size: 7 KB

No clinical trials found for this company.

No clinical products found for this company.